# The biology and role of CD44 in cancer progression: therapeutic implications

**Authors:** Chen Chen, Shujie Zhao, Anand Karnad, James W. Freeman

PMC · DOI: 10.1186/s13045-018-0605-5 · Journal of Hematology & Oncology · 2018-05-10

## TL;DR

This paper reviews the role of CD44 in cancer progression and its potential as a therapeutic target.

## Contribution

The paper provides a comprehensive review of CD44's structural and functional properties in cancer.

## Key findings

- CD44 overexpression is linked to cancer stem cells and tumor progression.
- CD44 variants (CD44v) are associated with metastasis and EMT regulation.
- CD44 signaling promotes cell survival, motility, and proliferation in cancer.

## Abstract

CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently shows alternative spliced variants that are thought to play a role in cancer development and progression. Hyaluronan, the main ligand for CD44, binds to and activates CD44 resulting in activation of cell signaling pathways that induces cell proliferation, increases cell survival, modulates cytoskeletal changes, and enhances cellular motility. The different functional roles of CD44 standard (CD44s) and specific CD44 variant (CD44v) isoforms are not fully understood. CD44v contain additional peptide motifs that can interact with and sequester growth factors and cytokines at the cell surface thereby functioning as coreceptors to facilitate cell signaling. Moreover, CD44v were expressed in metastasized tumors, whereas switching between CD44v and CD44s may play a role in regulating epithelial to mesenchymal transition (EMT) and in the adaptive plasticity of cancer cells. Here, we review current data on the structural and functional properties of CD44, the known roles for CD44 in tumorigencity, the regulation of CD44 expression, and the potential for targeting CD44 for cancer therapy.

## Linked entities

- **Genes:** CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960]
- **Proteins:** CD44 (CD44 molecule (IN blood group)), cd44.S (CD44 molecule (IN blood group) S homeolog)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** NANOG (Nanog homeobox) [NCBI Gene 79923], STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, MSN (moesin) [NCBI Gene 4478] {aka HEL70, IMD50}, MIR301A (microRNA 301a) [NCBI Gene 407027] {aka MIR301, MIRN301, MIRN301A, mir-301a}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, ESRP1 (epithelial splicing regulatory protein 1) [NCBI Gene 54845] {aka DFNB109, RBM35A, RMB35A}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CS (citrate synthase) [NCBI Gene 1431], MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, Fdxr (ferredoxin reductase) [NCBI Gene 14149] {aka AR}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CS-E [NCBI Gene 1433], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, FGFR2 (fibroblast growth factor receptor 2) [NCBI Gene 2263] {aka BBDS, BEK, BFR-1, CD332, CEK3, CFD1}, Cndp2 (CNDP dipeptidase 2) [NCBI Gene 66054] {aka 0610010E05Rik, Cn2, Dip-2, Pep-1, Pep1}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, TCF4 (transcription factor 4) [NCBI Gene 6925] {aka CDG2T, E2-2, FCD2, FECD3, ITF-2, ITF2}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, MIR143 (microRNA 143) [NCBI Gene 406935] {aka MIRN143, mir-143}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Hsp86-ps2 (heat shock protein 86, pseudogene 2) [NCBI Gene 111042] {aka 86kDa, Hsp86-3, Hsp90}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, ERVK-15 (endogenous retrovirus group K member 15) [NCBI Gene 100616443] {aka P1.10, c7_C}, HAS1 (hyaluronan synthase 1) [NCBI Gene 3036] {aka HAS}, Pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 18706] {aka 6330412C24Rik, caPI3K, p110, p110alpha}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, SRGN (serglycin) [NCBI Gene 5552] {aka PPG, PRG, PRG1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], Met (met proto-oncogene, receptor tyrosine kinase) [NCBI Gene 17295] {aka HGF, HGFR, Par4, c-Met}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, ATF3 (activating transcription factor 3) [NCBI Gene 467], CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, SNORD3P4 (small nucleolar RNA, C/D box 3 pseudogene 4) [NCBI Gene 26842] {aka RNU3P4, U3, U3.6}
- **Diseases:** EDA (MESH:D000092225), glioma (MESH:D005910), CRC (MESH:D015179), BPH (MESH:D011470), PanIN lesions (MESH:D009059), melanoma (MESH:D008545), adenoma (MESH:D000236), lung cancer (MESH:D008175), lymph node (MESH:D000072717), tumorigenic (MESH:D002471), PCa (MESH:D011471), gastric (MESH:D013272), osteosarcoma (MESH:D012516), CLL (MESH:D015451), cytotoxic (MESH:D064420), hepatocellular carcinoma (MESH:D006528), skin toxicities (MESH:D012871), lymph node metastasis (MESH:D008207), Gastrointestinal cancer (MESH:D005770), prostate tumor (MESH:D011472), SCID (MESH:D053632), leukemia (MESH:D007938), MDR (MESH:D018088), ovarian cancer (MESH:D010051), PDAC (MESH:D021441), inflammatory (MESH:D007249), Gastric cancer (MESH:D013274), CS (MESH:C535787), adenocarcinomas (MESH:D000230), Bladder cancer (MESH:D001749), leiomyosarcoma (MESH:D007890), tumorigenesis (MESH:D063646), Pancreatic cancer (MESH:D010190), Lung metastasis (MESH:D009362), Glioblastoma (MESH:D005909), neuroblastoma (MESH:D009447), triple negative breast cancer (MESH:D064726), combined immune deficiency (MESH:D016511), HGPIN (MESH:D019048), pancreatic intraepithelial neoplasia (MESH:D002578), oral cancer (MESH:D009062), Cancer (MESH:D009369), non-small cell lung cancers (MESH:D002289), Breast cancer (MESH:D001943), HNSCC (MESH:D000077195), triple (MESH:C536008), epidermoid carcinoma (MESH:D002294), metastatic (MESH:D000092182), cervical cancer (MESH:D002583), Colorectal adenocarcinomas (MESH:D003110),  (MESH:D018450)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Zingiber officinale (ginger, species) [taxon 94328], Homo sapiens (human, species) [taxon 9606], Silybum marianum (blessed milkthistle, species) [taxon 92921], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** BW5147 T lymphoma — Mus musculus (Mouse), Mouse lymphoma, Cancer cell line (CVCL_3896), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), NB4-LR1 — Homo sapiens (Human), Acute promyelocytic leukemia with PML-RARA, Cancer cell line (CVCL_8811), SKOV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), HPAC — Homo sapiens (Human), Pancreatic adenocarcinoma, Cancer cell line (CVCL_3517), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), KHOS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_2546), Hela — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), L3.6pl — Homo sapiens (Human), Pancreatic adenosquamous carcinoma, Cancer cell line (CVCL_0384), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), MiaPaCa-2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428), BSp73ASML — Bos taurus (Bovine), Finite cell line (CVCL_3657), MOC1 — Mus musculus (Mouse), Squamous cell carcinoma of the mouse oral cavity, Cancer cell line (CVCL_ZD32), Capan-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0237), DU145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), BPEC-T — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_3174), COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), U-2OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), MOC2, 7, 10 — Mus musculus (Mouse), Squamous cell carcinoma of the mouse oral cavity, Cancer cell line (CVCL_ZD35), HT29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), MOC2 — Mus musculus (Mouse), Squamous cell carcinoma of the mouse oral cavity, Cancer cell line (CVCL_ZD33), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), PC3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), PaTu II — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_4013), Panc-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), CFPAC-1 — Homo sapiens (Human), Cystic fibrosis, Cancer cell line (CVCL_1119), LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), HepG2iso — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), BxPC-3 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0186), NIH/3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), H4C4 — Mus musculus (Mouse), Hybridoma (CVCL_B7BB), Capan-2 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0026), AsPC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0152), CV-1 — Chlorocebus aethiops (Green monkey), Finite cell line (CVCL_0229)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC5946470/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC5946470/full.md

## References

201 references — full list in the complete paper: https://tomesphere.com/paper/PMC5946470/full.md

---
Source: https://tomesphere.com/paper/PMC5946470